(Reuters) – Pfizer Inc and United Nations-backed Medicines Patent Pool (MPP) are in advanced talks on a licensing agreement that would allow qualified third parties to manufacture and supply the U.S. drugmaker’s oral antiviral pill candidate, pending regulatory nod, the MPP told Reuters.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Arun Koyyur)
